{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T08:36:12Z","timestamp":1794818172401,"version":"4.9.1"},"reference-count":65,"publisher":"American Medical Association (AMA)","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,4,20]]},"DOI":"10.1001\/jama.2021.0716","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:09:50Z","timestamp":1618963790000},"page":"1545","source":"Crossref","is-referenced-by-count":136,"title":["Oral Antiplatelet Therapy After Acute Coronary Syndrome"],"prefix":"10.1001","volume":"325","author":[{"given":"Hassan","family":"Kamran","sequence":"first","affiliation":[{"name":"Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Jneid","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas"},{"name":"Section of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waleed T.","family":"Kayani","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas"},{"name":"Section of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn N.","family":"Levine","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas"},{"name":"Section of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Nambi","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas"},{"name":"Section of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umair","family":"Khalid","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas"},{"name":"Section of Cardiology, Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"jrv210002r1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association.","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"issue":"25","key":"jrv210002r2","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1161\/CIR.0000000000000133","article-title":"2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes: executive summary.","volume":"130","author":"Amsterdam","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"jrv210002r3","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","article-title":"A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF\/AHA\/SCAI guideline for percutaneous coronary intervention, 2011 ACCF\/AHA guideline for coronary artery bypass graft surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA\/ACC guideline for the management of patients with non\u2013ST-elevation acute coronary syndromes, and 2014 ACC\/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery.","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"jrv210002r4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.007541","article-title":"Risk-benefit profile of longer-than-1-year dual-antiplatelet therapy duration after drug-eluting stent implantation in relation to clinical presentation a pairwise meta-analysis of 6 trials and 21 457 patients.","volume":"12","author":"Palmerini","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"jrv210002r5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"jrv210002r6","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.","author":"Collet","journal-title":"Eur Heart J"},{"issue":"4","key":"jrv210002r7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11883-014-0401-9","article-title":"Pathophysiology of acute coronary syndrome.","volume":"16","author":"Santos-Gallego","year":"2014","journal-title":"Curr Atheroscler Rep"},{"issue":"7","key":"jrv210002r8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jacc.2008.04.050","article-title":"Coronary artery spasm as a frequent cause of acute coronary syndrome: the CASPAR (Coronary Artery Spasm in Patients With Acute Coronary Syndrome) study.","volume":"52","author":"Ong","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"jrv210002r9","doi-asserted-by":"publisher","first-page":"e891","DOI":"10.1161\/CIR.0000000000000670","article-title":"Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association.","volume":"139","author":"Tamis-Holland","year":"2019","journal-title":"Circulation"},{"issue":"23","key":"jrv210002r10","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1001\/jama.2019.15736","article-title":"Coronary microvascular dysfunction causing cardiac ischemia in women.","volume":"322","author":"Wei","year":"2019","journal-title":"JAMA"},{"issue":"7","key":"jrv210002r11","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.120.052008","article-title":"Coronary optical coherence tomography and cardiac magnetic resonance imaging to determine underlying causes of myocardial infarction with nonobstructive coronary arteries in women.","volume":"143","author":"Reynolds","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"jrv210002r13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/2048872612441582","article-title":"Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease.","volume":"1","author":"Badimon","year":"2012","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"2","key":"jrv210002r14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/cvr\/cvt115","article-title":"Biological responses in stented arteries.","volume":"99","author":"Chaabane","year":"2013","journal-title":"Cardiovasc Res"},{"issue":"2","key":"jrv210002r15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1001\/jama.2013.7086","article-title":"Medical management after coronary stent implantation: a review.","volume":"310","author":"Brilakis","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"jrv210002r16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.15420\/ecr.2018:8:2","article-title":"The newest generation of drug-eluting stents and beyond.","volume":"13","author":"Lee","year":"2018","journal-title":"Eur Cardiol"},{"issue":"1","key":"jrv210002r17","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1161\/CIRCINTERVENTIONS.110.957332","article-title":"Vascular smooth muscle cell proliferation in restenosis.","volume":"4","author":"Marx","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"issue":"1","key":"jrv210002r18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/jcmm.2019.23.issue-1","article-title":"The effects of stenting on coronary endothelium from a molecular biological view: time for improvement?","volume":"23","author":"Cornelissen","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"5","key":"jrv210002r19","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1172\/JCI121985","article-title":"Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1\/thromboxane A2.","volume":"129","author":"Lucotti","year":"2019","journal-title":"J Clin Invest"},{"issue":"6","key":"jrv210002r20","doi-asserted-by":"publisher","first-page":"3A","DOI":"10.1016\/0735-1097(88)92635-6","article-title":"Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.","volume":"12","year":"1988","journal-title":"J Am Coll Cardiol"},{"issue":"7329","key":"jrv210002r21","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.","volume":"324","author":"Antithrombotic Trialists\u2019 Collaboration","year":"2002","journal-title":"BMJ"},{"issue":"7","key":"jrv210002r22","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1056\/NEJM198308183090703","article-title":"Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study.","volume":"309","author":"Lewis","year":"1983","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv210002r23","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"jrv210002r24","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"issue":"9038","key":"jrv210002r25","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).","volume":"348","author":"CAPRIE Steering Committee","year":"1996","journal-title":"Lancet"},{"issue":"19","key":"jrv210002r26","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.","volume":"288","author":"Steinhubl","year":"2002","journal-title":"JAMA"},{"issue":"12","key":"jrv210002r27","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa050522","article-title":"Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.","volume":"352","author":"Sabatine","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv210002r28","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes.","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"issue":"19","key":"jrv210002r29","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction.","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"jrv210002r30","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes.","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"issue":"14","key":"jrv210002r31","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","article-title":"Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.","volume":"367","author":"Roe","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"jrv210002r32","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1056\/NEJMoa1308075","article-title":"Pretreatment with prasugrel in non\u2013ST-segment elevation acute coronary syndromes.","volume":"369","author":"Montalescot","year":"2013","journal-title":"N Engl J Med"},{"issue":"16","key":"jrv210002r33","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or prasugrel in patients with acute coronary syndromes.","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv210002r34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.","volume":"366","author":"Tricoci","year":"2012","journal-title":"N Engl J Med"},{"issue":"15","key":"jrv210002r35","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events.","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"issue":"9281","key":"jrv210002r36","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"issue":"16","key":"jrv210002r37","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/eurheartj\/ehp296","article-title":"P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.","volume":"30","author":"Wallentin","year":"2009","journal-title":"Eur Heart J"},{"issue":"7","key":"jrv210002r38","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/FPC.0b013e3283385420","article-title":"Clopidogrel pathway.","volume":"20","author":"Sangkuhl","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"jrv210002r39","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2147\/VHRM.S5699","article-title":"Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.","volume":"5","author":"Norgard","year":"2009","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"jrv210002r40","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1161\/CIRCULATIONAHA.109.921502","article-title":"Prasugrel.","volume":"122","author":"Wiviott","year":"2010","journal-title":"Circulation"},{"issue":"6","key":"jrv210002r42","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1177\/0091270011406280","article-title":"Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy.","volume":"52","author":"Riesmeyer","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"jrv210002r43","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.113.002303","article-title":"Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.","volume":"128","author":"Roe","year":"2013","journal-title":"Circulation"},{"issue":"10","key":"jrv210002r44","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/phar.2014.34.issue-10","article-title":"Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.","volume":"34","author":"Dobesh","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"6","key":"jrv210002r45","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1177\/2048872614554108","article-title":"Dyspnoea management in acute coronary syndrome patients treated with ticagrelor.","volume":"4","author":"Parodi","year":"2015","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"9711","key":"jrv210002r46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.","volume":"375","author":"Cannon","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"jrv210002r47","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1161\/CIRCULATIONAHA.111.047498","article-title":"Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.","volume":"124","author":"Mahaffey","year":"2011","journal-title":"Circulation"},{"issue":"14","key":"jrv210002r49","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA 2P\u2013TIMI 50.","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"jrv210002r50","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jcin.2013.06.015","article-title":"Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients.","volume":"6","author":"Tada","year":"2013","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"jrv210002r51","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jacc.2016.03.512","article-title":"Duration of Dual Antiplatelet Therapy: a systematic review for the 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"68","author":"Bittl","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"jrv210002r52","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention.","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"issue":"14","key":"jrv210002r53","first-page":"1034","article-title":"Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11?473 patients.","volume":"38","author":"Palmerini","year":"2017","journal-title":"Eur Heart J"},{"issue":"24","key":"jrv210002r54","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: The STOPDAPT-2 randomized clinical trial.","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"21","key":"jrv210002r55","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI.","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"jrv210002r56","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial.","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"issue":"6","key":"jrv210002r57","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1161\/CIRCULATIONAHA.120.046251","article-title":"The safety and efficacy of aspirin discontinuation on a background of a P2Y12 inhibitor in patients after percutaneous coronary intervention: a systematic review and meta-analysis.","volume":"142","author":"O\u2019Donoghue","year":"2020","journal-title":"Circulation"},{"issue":"6","key":"jrv210002r58","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jacc.2004.08.070","article-title":"Aspirin resistance and atherothrombotic disease.","volume":"46","author":"Mason","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"jrv210002r59","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.jacc.2005.06.058","article-title":"Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease.","volume":"46","author":"Maree","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"jrv210002r60","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel.","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv210002r61","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.amjcard.2008.11.048","article-title":"Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.","volume":"103","author":"Giusti","year":"2009","journal-title":"Am J Cardiol"},{"issue":"22","key":"jrv210002r62","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting.","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"jrv210002r63","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1161\/CIRCULATIONAHA.113.007524","article-title":"High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: a landmark analysis of the ARCTIC study.","volume":"129","author":"Montalescot","year":"2014","journal-title":"Circulation"},{"issue":"19","key":"jrv210002r64","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1016\/j.jacc.2007.07.053","article-title":"Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non\u2013ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.","volume":"50","author":"Cannon","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"jrv210002r65","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.","volume":"119","author":"Mega","year":"2009","journal-title":"Circulation"},{"key":"jrv210002r12","doi-asserted-by":"crossref","DOI":"10.1017\/UPO9781922064004","volume-title":"Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists","author":"Fitridge","year":"2011"},{"key":"jrv210002r41","unstructured":"Effient (prasugrel). Prescribing information. Eli Lilly and Co; 2009. Published 2009. Revised March 2019. Accessed March 23, 2021. https:\/\/pi.lilly.com\/us\/effient.pdf"},{"key":"jrv210002r48","unstructured":"Brilinta (ticagrelor). Prescribing information. AstraZeneca; 2011. Revised November 2020. Accessed March 23, 2021. https:\/\/www.azpicentral.com\/brilinta\/brilinta.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2778801\/jama_kamran_2021_rv_210002_1626102044.68693.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T17:58:17Z","timestamp":1671904697000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2778801"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":65,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2021,4,20]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2021.0716","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,20]]}}}